Jeffrey Crowley, MD
Dermatology · Bakersfield, CANPI 1073500278
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $1,361,290 of the $2,133,653 with a category attached, or 63.8%. 47 manufacturers reported payments, led by AbbVie at 30.3% of the total. Among dermatology clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 2,340 payments — averaging $911.82 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$647K
- UCB, Inc.$240K
- Janssen Scientific Affairs, LLC$218K
- Lilly USA, LLC$193K
- Johnson & Johnson$174K
- E.r. Squibb & Sons, L.L.C.$150K
- plus $514K from 41 others
Across 201 payments — averaging $4329.88 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$312K
- AbbVie$261K
- UCB SA$170K
- Regeneron$46K
- UCB Biosciences Inc.$23K
- Dermira, Inc.$16K
- plus $43K from 5 others
What the payments were for
- Consulting fees$621,68129%
- Speaking & faculty fees$1,361,29064%
- Travel & lodging$111,7265%
- Food & beverage$38,7882%
- Education$1680%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,133,653 in reported general payments places this provider in the 95th percentile of 1,875 dermatology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Dupixent SyringeDupilumab | 77 | $304,767 |
| Dupixent PenDupilumab | 30 | $107,607 |
| Fluorouracil | 80 | $6,482 |
| Clobetasol Propionate | 100 | $4,203 |
| Triamcinolone Acetonide | 298 | $3,804 |
| Fluocinonide | 59 | $2,357 |
| Minocycline Hcl | 83 | $2,321 |
| Doxycycline Hyclate | 63 | $2,194 |
| Betamethasone Dipropionate | 39 | $1,704 |
| Metronidazole | 22 | $1,558 |
| Ketoconazole | 113 | $1,534 |
| ValacyclovirValacyclovir Hcl | 29 | $645 |
| Cephalexin | 137 | $520 |
| Hydroxychloroquine Sulfate | 30 | $483 |
| Prednisone | 48 | $435 |
Paid to pharmacies, not to this prescriber.
Other dermatology in Bakersfield
- Paul YamauchiSanta Monica$2.9M
- Jennifer SoungSanta Ana$2.8M
- Robert GreenbergLivermore$2.6M
- Neal BhatiaSan Diego$2.5M
- April ArmstrongLos Angeles$2.3M
- Jashin WuCorona$2M
- Raja SivamaniSacramento$1.9M
- Tien NguyenFountain Valley$1.2M
- Tina BhutaniSan Francisco$1.1M
- Jenny MuraseMountain View$1.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.